 |
|
| Company | Becton Dickinson and Company |
| Headquarters | 1 Becton Drive, Franklin Lakes, NJ, USA |
| Chairman and CEO | Vincent A. Forlenza |
| CFO | Christopher Reidy |
| Industry | Medical Equipment |
| Founders | Maxwell W. Becton and Fairleigh S. Dickinson |
| Founded | 1897 |
| NYSE stock symbol | BDX |
| Revenue | $8.446 billion (2014) |
| Net income | $1,185 million (2014) |
| Earnings per share | $5.99 USD (2014) |
| Employees | 30,619 (2014) |
| Website | http://www.bd.com/ |
| Investor relations contact number: | 1-800-284-6845 |
Becton Dickinson and Company is a multinational American medical technology company that manufactures medical supplies, devices, laboratory equipment and diagnostic products.
It is headquartered in Franklin Lakes, New Jersey, USA, with a team of approximately 30,000 employees in more than 50 countries worldwide.
Becton Dickinson was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson. In 1906 Becton, Dickinson and Company (also known as “BD”) was incorporated under the laws of the State of New Jersey.
It was one of the first of its kind to produce glass syringes in the US.
The company is comprised of the following business segments:
BD Medical – produces and supplies medical devices, including: needles and syringes, intravenous catheters, safety-engineered and auto-disable devices, prefillable drug delivery systems, prefilled IV flush syringes, insulin Syringes and pen needles, regional anesthesia needles and trays, self-injection systems, sharps disposal containers, closed-system drug transfer devices.
BD Diagnostics – focuses on the collection and transportation of diagnostics specimens. Products and services include: Integrated systems for specimen collection, safety-engineered blood collection products and systems, automated blood culturing systems, molecular testing systems for infectious diseases and women’s health, microorganism identification and drug susceptibility systems, liquid-based cytology systems for cervical cancer screening, rapid diagnostic assays, plated media, and microbiology laboratory automation.
BD Biosciences – produces diagnostic and research tools, including: fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits for cell analysis, reagent systems for life science research, cell imaging systems, and cell culture media and supplements for biopharmaceutical manufacturing.
The company is publicly traded on the New York Stock Exchange (NYSE) under the stock ticker symbol ‘BDX’.
| Income statement data (in $ millions) | 2014* | 2013* |
| Revenues | $8,446 | $8,054 |
| Research and development expense | $550 | $494 |
| Total operating costs and expenses | $6,840 | $6,800 |
| Operating income | $1,606 | $1,254 |
| Income from continuing operations before income taxes | $1,522 | $1,165 |
| Income tax provision | $337 | $236 |
| Income from continuing operations | $1,185 | $929 |
| Income from discontinued operations | $ – | $364 |
| Net income | $1,185 | $1,293 |
| Comprehensive income | $699 | $1,579 |
| Balance sheet data (in $ millions) | ||
| Total assets | $12,447 | $12,149 |
| Long term debt | $3,768 | $3,763 |
| Total shareholders’ equity | $5,053 | $5,043 |
| Common share data (in $) | ||
| Earnings per Common Share – Basic | $6.13 | $6.63 |
| Earnings per Common Share – Diluted | $5.99 | $6.49 |
| Cash flow data (in $ millions) | ||
| Net cash provided by continuing operating activities | $1,746 | $1,717 |
| Net cash used for continuing investing activities | $(948) | $(311) |
| Net cash used for continuing financing activities | $(807) | $(968) |
| Opening cash and equivalents | $1,890 | $1,671 |
| Closing cash and equivalents | $1,861 | $1,890 |
*Years Ended September 30
Source: “Becton Dickinson and Company Form 10-K 2014”